![N-[2-Hydroxy-1-(hydroxymethyl)ethyl]hexadecanamide](https://static.cymitquimica.com/cas-image/445781-n-2-hydroxy-1-hydroxymethyl-ethyl-hexadecanamide.png)
CAS: 126127-31-9 - N-[2-Hydroxy-1-(hydroxymethyl)ethyl]hexadecanamide
Fórmula:C19H39NO3
InChI:InChI=1S/C19H39NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-19(23)20-18(16-21)17-22/h18,21-22H,2-17H2,1H3,(H,20,23)
Chave InChI:InChIKey=MZUNFYMZKTWADX-UHFFFAOYSA-N
SMILES:O=C(NC(CO)CO)CCCCCCCCCCCCCCC
- Sinónimos:
- Hexadecanamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-
- N-[2-Hydroxy-1-(Hydroxymethyl)Ethyl]-Hexadecanamide
- Palmitoyl Serinol
| Marca | Dados do produto | Pureza | Gama de preços | Estimativa de entrega |
|---|---|---|---|---|
 | Hexadecanamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]- REF: IN-DA000RQCCAS: 126127-31-9 | - - - | A consultar | Qui 02 Jan 25 |
 | N-Palmitoyl serinol REF: 3D-BFA12731CAS: 126127-31-9 | Min. 95% | A consultar | Ter 11 Fev 25 |
 | Palmitoyl serinol REF: TM-T60957CAS: 126127-31-9 | - - - | 93,00 €~1.277,00 € | Ter 18 Fev 25 |
![Hexadecanamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-](https://static.cymitquimica.com/products/IN/thumb/DA000RQC.jpg)
Hexadecanamide, N-[2-hydroxy-1-(hydroxymethyl)ethyl]-
CAS:126127-31-9
Fórmula:
C19H39NO3
Peso molecular:
329.5179
Ref: IN-DA000RQC
| Tamanho indefinido | A consultar |
Entrega estimada em Estados Unidos, Quinta-feira 2 de Janeiro de 2025
N-Palmitoyl serinol
CAS:126127-31-9
N-Palmitoyl serinol is an analog of palmitic acid. It has been shown to be effective …
Fórmula:
C19H39NO3
Pureza:
Min. 95%
Peso molecular:
329.5 g/mol
Ref: 3D-BFA12731
| 100mg | A consultar |
Entrega estimada em Estados Unidos, Terça-feira 11 de Fevereiro de 2025
Palmitoyl serinol
CAS:126127-31-9
Anticancer agent 110 is an anticancer compound with cytotoxic, antitumor and antileukemic activities.
Fórmula:
C19H39NO3
Cor e Forma:
Liquid
Peso molecular:
329.52
Ref: TM-T60957
| 5mg | 93,00 € | ||
| 10mg | 178,00 € | ||
| 50mg | 719,00 € | ||
| 100mg | 1.277,00 € |
Entrega estimada em Estados Unidos, Terça-feira 18 de Fevereiro de 2025
